Earlier in May 2026, Pfizer reported positive Phase 2 results for its investigational 25‑valent pneumococcal conjugate ...

May 20 (Reuters) - Pfizer said on Wednesday its experimental pneumococcal vaccine showed significantly stronger immune ...

Pfizer (PFE) is back in focus after two R&D milestones, a broader European indication for hemophilia drug HYMPAVZI and ...

Pfizer has upped the ante in the increasingly competitive market for pneumococcal vaccines with mid-stage clinical data for a ...

Pfizer Inc. PFE on Wednesday reported positive Phase 2 data for its investigational 25-valent pneumococcal conjugate vaccine ...

Pfizer Inc. (NYSE: PFE) today announced data from its Phase 2 study ( NCT06524414) evaluating the safety, tolerability and immunogenicity of a four-dose series of its investigational 25-valent ...

Add Yahoo as a preferred source to see more of our stories on Google. This electron microscopic image provided by the Centers for Disease Control and prevention depicts two, round-shaped, ...

Add Yahoo as a preferred source to see more of our stories on Google. Apr. 9—(StatePoint) Pneumococcal pneumonia is a potentially serious bacterial lung disease that can disrupt your life for weeks ...

Please provide your email address to receive an email when new articles are posted on . Researchers compared the 21-valent vaccine to a combination of a 15-valent and 23-valent vaccines. Fewer adverse ...

U.S. health officials on Wednesday recommended that people 50 and older get a shot against bacteria that can cause pneumonia and other dangerous illnesses. The recommendation was made by a scientific ...

The FDA approved a 21-valent pneumococcal conjugate vaccine (Capvaxive) for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults, Merck announced on Monday. Specifically ...